In Reply Our study1 was initially submitted in January 2015 as an abstract for the 2015 American Society of Clinical Oncology Annual Meeting and was accepted in March 2015 as an oral presentation; it was subsequently submitted to JAMA Oncology in April 2015 before the study by van Gool et al2 appeared online. The goal of our study was to address whether hypermutated (microsatellite-unstable [MSI]/POLE-mutant) endometrial cancers (ECs) were more immunogenic compared with microsatellite-stable (MSS) ECs, and not whether this association may account for the improved survival of POLE-mutated tumors; accordingly, no reference was made to studies reporting an association of POLE-mutated tumors with improved survival.
Howitt BE, Shukla SA, Konstantinopoulos PA. Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers—Reply. JAMA Oncol. 2016;2(1):141-142. doi:10.1001/jamaoncol.2015.3903